Archive for the ‘Transmission’ Category

Red Meat Allergy Surges As WEF’s ‘Human Engineering’ Blueprint Becomes Reality

https://thepeoplesvoice.tv/red-meat-allergy-surges-across-america-as-wefs-human-engineering-blueprint-becomes-reality/

Red Meat Allergy Surges Across America as WEF’s ‘Human Engineering’ Blueprint Becomes Reality

Fact checked by The People’s Voice Community

May 13, 2025 Baxter Dmitry

A dangerous tick-borne illness that leaves victims unable to eat red meat is quietly spreading across the U.S., raising alarms years after the World Economic Forum floated the idea of using the ticks in a “human engineering” scheme to curb global meat consumption.

Known as Alpha-gal Syndrome (AGS), the condition is caused by the bite of the Lone Star tick, which injects a sugar molecule called alpha-gal into the body. This molecule triggers a potentially severe allergic reaction to red meat and other mammal-based products.

According to the Centers for Disease Control and Prevention (CDC), more than 110,000 suspected cases of Alpha-gal Syndrome were reported between 2010 and 2022, however the true number is believed to be much higher due to underdiagnosis and lack of awareness in the medical community.

“Every week, I hear of more cases near me,” said Dr Ben Braddock. “Some farmers and ranchers can’t even go near their livestock. The government needs to treat this with much more urgency.”

In a 2016 panel discussion at the World Science Festival, bioethicist Dr. S. Matthew Liao explored speculative ideas about “human engineering” to address climate change, including reducing meat consumption.

Liao mentioned the Lone Star tick’s possible role in “engineering” humanity by causing red meat allergies, heralding the possibility as an example of how biology can influence dietary habits.  (See link for article and video)

______________

**Comment**

Alpha Gal Syndrome (AGS) recently made The Jimmy Dore Show.  He shares that Bill Gates, who regularly partnered with USAID, and who is a prominent globalist who wants the world’s population to be reduced, funded research into genetically engineered cattle. Suddenly, people have meat allergies.

‘Fact checkers’ are frantically debunking this, by stating only the lone star tick transmits it, but here’s the deal: AGS is relatively new.  Scientists don’t have a clue what and how many ticks can transmit it.

Gates is also behind the manufacture of GM mosquitos that have been released creating hybrid wild mosquitoes.

History has proven that proclaiming a tick only transmits this or that eventually ends up being proven false.

So far the following ticks have been identified as perps for AGS:

  • Asian longhorned tick has caused AGS in Asia, but the tick has made its way here to the U.S.
  • Cayenne tick found in South Texas and Florida has also been linked to AGS in Central America.
  • As recently as April, 2025 a pair of research papers for the FIRST TIME have identified that black-legged ticks and western black-legged ticks can also cause AGS. Please note this evidence has not been obtained by lab experiments, but a case study of a woman who developed the condition after being bitten by a western black-legged tick and a case study of another woman after being bitten by a black-legged tick.

Until ticks, birds, mammals, and reptiles get the memo that they aren’t supposed to cross boundary lines, good luck stopping them from showing up where they shouldn’t be and transmitting stuff they shouldn’t have!

I find it mind boggling that there are NO lab experiments determining what ticks transmit this considering the anaphylactic shock from it can be fatal

Plus, are you sitting down?  

  • You don’t even need a tick bite to get this.  To my knowledge, the only reason ticks have been blamed at all is because certain tick’s saliva contains trace quantities of a sugar, alpha-gal, a known human irritant that many researchers and clinicians believe induces the dangerous allergic responses that are the hallmark of AGS.  But, just because you believe something, doesn’t make it true.
  • Symptoms are often delayed making it hard to pinpoint the cause.
  • There are no insurance billing codes for AGS.
  • Since it’s not a reportable illness to the CDC, nobody has a clue about prevalence.
  • Not everyone bitten by a tick containing AGS will develop AGS and not everyone who carries antibodies to AGS will get AGS, and a positive test does not always mean a person has been exposed to alpha-gal.  Confused yet?
  • The number of lab-confirmed cases grew from 12 in 2009 to over 34,000 in 2019.
  • There’s no treatment for it – just avoiding anything that triggers symptoms.
  • Similar to Lyme, you can have coinfections with AGS, making symptoms and treatment even more challenging

Some farmers can’t go near their livestock, and for some, it’s not just meat, it’s any product made from mammals like lard, milk, cream, ice cream, cheese, gelatin, lanolin, glycerin, collagen, jello, medications, anti-venom, surgical mesh, carrageenan, ‘natural flavorings’, tallow, and vaccines.

Regarding anaphylaxis:  A 2021 study described cases of severe anaphylaxis in individuals receiving vaccines containing gelatin. The authors stated:

“Gelatin-containing vaccines should be administered with caution or avoided in patients with AGS because of their high potential to activate basophils indicating a risk for anaphylaxis.”

And of course the ‘overheating planet’ and milder winters are repeated like a mantra as the cause of all the mayhem due to ticks supposedly expanding their ranges, which has been disproven by independent science.  

Nobody ever wants to talk about the very real 50 year history of geoengineering – spraying our skies with toxic elements in the name of ‘climate change,’ or the fact our own government has experimented on and force fed ticks with pathogens and then dumped them from airplanes, conducted biological experiments on allied soldiers, and experimented on prisoners.

The Jimmy Dore Show presented that there is a new patented FDA approved genetically modified breed of pig called GalSafe pigs, which are modified to eliminate alpha-gal so those suffering from AGS can still eat pork.

The pPL657 rDNA construct which integrated into the genome consisted of the DNA sequence used to disrupt the GGTA1 gene and the sequence of the neomycin phosphotransferase (nptII) gene, an antimicrobial resistance marker.

Because the nptII gene is a known antimicrobial resistance marker, it was used as a molecular biology tool during the development of the IGA.

Based on evidence from the scientific literature, information in databases of the DNA and amino acid sequences of known food allergens and toxins, and the permitted use of the nptII gene in genetically engineered plants intended for human food, FDA concluded that it is unlikely that the protein encoded by the nptII gene is a food allergen or other human food safety hazard. Source

Well, we’ll see how that one works out…..

What do you bet that this too will lead to another patentable product?

Category:

Activism, Alpha Gal Meat Allergy, Ticks, Transmission

Lyme Disease Increases Risk for Multiple Gynecological Conditions

https://www.medrxiv.org/content/10.1101/2025.03.03.25323258v1

Lyme disease increases risk for multiple gynecological conditions

Paige S. Hansen Colburn, Grace Blacker, Sarah Galloway, Qingying Feng, Prasanna S. Padmanabham, Guido Pisani, Brandon T. Lee, Grace Loeser, Monika W Perez, Kunzan Liu, Jade Kuan, Emelia von Saltza, Satu Strausz, Lisa M. Mattei, Sophie VanderWeele, George R. Nahass, Amie Kitjasateanphun,  Rangarajan Bharadwaj, Hari-Hara SK Potula, Maia Atzmon Shoham, Finngen, Victoria L. Mascetti, Eric Gars, Hanna M Ollila, Kaylon L. Bruner-Tran, Irving Weissman,  Sixian You, Beth Pollack, Linda Griffith, Nasa Sinnott-Armstrong,  Michal Caspi Tal
doi: https://doi.org/10.1101/2025.03.03.25323258

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Abstract

Lyme disease (LD) is an illness caused by the spirochete Borrelia burgdorferi (B. burgdorferi). Borrelia is known to disseminate through organs, including the skin, joints, spinal cord, bladder, and heart, leading to Lyme arthritis, neuroborreliosis, and Lyme carditis. While previous studies have investigated the impact of LD on pregnancy in both mice and humans and have found the presence of B. burgdorferi in the uterus of mice, we studied the impact of LD on the non-pregnant female reproductive tract. We use a mouse model for LD and find an ongoing and severe infection of the reproductive tract of female mice, which persists up to 15-months post-inoculation. This infection results in uterine glandular cysts and endometrial hyperplasia as well as vaginal epithelial thickening, polymorphonuclear and mononuclear cell epithelial infiltration, and epithelial desquamation into the vaginal lumen. Strikingly, we find that age has an impact on the extent of gynecologic pathology such that aged female mice (1-year old) that are reproductively senescent have more gynecologic pathology with infection compared to young mice (15-weeks old) when infected for the same length of time. Using large-scale electronic healthcare record data, we report that LD additionally results in increased infection-associated risk of:

  1. menorrhagia (1.5-fold)
  2. miscarriage (1.62-fold)
  3. uterine fibroids (1.42-fold)
  4. endometriosis (1.93-fold)

Underreporting of gynecological outcomes is pervasive throughout many different infectious diseases, and LD-associated gynecological pathologies may have been similarly underappreciated in the field. This work suggests that further study of the female reproductive tract and the effects of B. burgdorferi infection therein will help clarify and expand the knowledge of myriad LD outcomes.

For more:

Category:

Lyme, research, Transmission

Prof. Holly Ahern’s Lyme Disease Comments to Australian Senate

https://www.lymedisease.org/holly-ahern-australian-senate/

Prof. Holly Ahern’s Lyme disease comments to Australian Senate

2/5/25

The Australian Senate has launched an inquiry into the access to diagnosis and treatment for people in Australia with tick-borne diseases. Professor Holly Ahern of the United States recently submitted the following written comments and was also asked to give verbal remarks. (See video at end of this article.)

Dear Committee Members:

I am a scientist, professor of microbiology, and co-founder of a Lyme disease advocacy organization in New York State. I am also the Scientific Advisor for the Focus on Lyme Foundation in Arizona, which has funded research on several projects directed at improving the state of diagnostic testing for Lyme disease and other tick-borne illnesses.

I have served on several state and federal committees convened to address the growing problem of tick-borne diseases in the United States, most recently the 2022 Dept. of Health and Human Services, Tick Borne Disease Working Group (TBDWG).

But most of all, I am mother of a daughter who went from a record setting collegiate All American swimmer to bed bound and disabled over the course of only a few weeks. She lost years of her life as a result of flawed medical guidelines that prioritize care for patients early in the infection, while providing only minimal guidance for the diagnosis and care of patients in later stages of the disease.

In my daughter’s case, we saw the tick bite but she developed no rash. Fever, profound fatigue, widespread pain, and other symptoms began months later, and were attributed to a viral illness. The difficulties we faced in getting her illness diagnosed and appropriately treated in 2010 match those of hundreds of thousands of other people with Lyme disease in the United States and Europe, and also in Australia.

Biologically complex organism

Lyme disease is a bacterial infection caused by a microbe with global distribution. They are transmitted to humans by several species of tick. The bacteria are biologically complex. They adapt and survive in environments that would kill most other bacteria.

During human infection, some subgroups (genospecies) of these bacteria linger in the bloodstream, while others disseminate to connective tissue-rich areas of the body. Regardless, infection triggers profound immune system and other physiological events, leading to a wide range of symptoms that vary significantly among patients and can be quite severe.

The standard medical definition implies that the overwhelming majority of Lyme borreliosis (Lyme disease) patients are infected with the same bacteria and have the same uniform disease presentation, which is straightforward to diagnose and treat. As defined, Lyme disease is caused by only a few specific genospecies of Borrelia (now named Borreliella). Several other genospecies of Borrelia are associated with diseases collectively referred to as “Relapsing Fever borreliosis.”

Differences between the two diseases are subtle. Relapsing Fever Borrelia fail to produce the skin manifestation (erythema migrans or “bull’s-eye” rash) that is noted in Lyme disease; however, other symptoms are very similar. Existing diagnostic tests for Lyme disease don’t detect infections caused by Relapsing Fever Borrelia.

Thus, a patient may be bitten by a tick and infected with a Relapsing Fever Borrelia, such as B. miyamatoi, show all the symptoms that a patient with Lyme disease would have, but may not be diagnosed or treated for the infection because the EM rash did not appear and/or the standard lab tests for Lyme disease were negative.  (See link for article)

_____________

For more:

Category:

Lyme, research, Testing, Ticks, Transmission, Treatment

N-of-1 Trials: The Only Hope for Lyme Patients & the Vaccine Injured

https://johncatanzaro.substack.com/p/n-of-1-trials-the-only-hope-for-long?

N-of-1 Trials: The Only Hope for Long COVID, Spike Protein Complications, and Vaccine-Injured Patients

Signal-Based Medicine | N-of-1 Trials

Decision Junction

Peter A. McCullough, MD, MPH
Nicolas Hulscher, MPH

Feb 03, 2025

The Current Dilemma

The current medical system is failing those suffering from Long COVID and vaccine injuries—patients are gaslit, dismissed, and left to deteriorate without real solutions. The reason? Our healthcare model is built around randomized controlled trials (RCTs), which were never designed for individualized treatment.

What Is an N-of-1 Trial?

An N-of-1 trial is a personalized, single-patient clinical study that aligns treatment based on the individual’s unique biomolecular response. Instead of relying on population-based statistics, this method uses real-time molecular surveillance, patient-specific peptide therapeutics, and adaptive treatment adjustments to achieve true precision medicine.

Unlike traditional one-size-fits-all drug development, N-of-1 trials are built around the patient—tracking their unique exome, transcriptome, and proteome to correct faulty molecular signaling at the source.

We do not have time to wait for mass-scale trials designed for bureaucratic approval pipelines rather than real-world recovery. Lives are deteriorating daily, careers are lost, and families are crumbling. The answer is clear: we need a personalized, adaptive medical model that responds to the patient in real-time—not a slow-moving, industry-driven system.

A Stark Illustration:

Recent breakthroughs in gene-based therapies have demonstrated impressive success in conditions like spinal muscular atrophy, sparking renewed hope for addressing complex neurogenetic diseases. However, many of these interventions are designed to target specific genetic variations, and the rigid structure of traditional clinical trials has created a severe bottleneck in innovation.

Economic and bureaucratic barriers ensure that commercial development is prioritized only for high-prevalence druggable genetic variants— those deemed profitable and feasible for large-scale trials. As a result, countless patients with rare or individualized molecular disruptions are left without viable treatment options, reinforcing the urgent need for N-of-1 trials that bypass these restrictive models and deliver precision-driven solutions in real-time.

Unfortunately, this progress has not extended to Long COVID and vaccine-related injuries, where patients are suffering from Spike-protein-induced immune dysregulation, severe cardiac damage, neuroinflammation, and persistent spike-related organ damage with no viable path to treatment.

The reason is clear: traditional clinical trial models prioritize druggable conditions with large, commercially profitable patient populations while existing N-of-1 trials are still shackled by the same flawed system, failing to deliver the personalized, compassionate care that patients with complex, individualized needs urgently require. The solution is simple: individualized N-of-1 trials must operate independently, untainted by the dysfunction of the current medical research model.

The Catastrophic Failure of RCTs in Chronic Disease

RCTs were designed for standardized drug testing, not complex, multi-systemic conditions like Long COVID and vaccine injuries. These illnesses vary drastically between individuals, yet the medical system continues to force them into rigid study parameters that discard individualized responses.

Why the System Is Broken:

• Deliberate Exclusion of the Suffering – Long COVID and vaccine-injured patients don’t fit neatly into RCT parameters, so they are ignored.

• Slow, Bureaucratic Approval Processes – Years-long trials mean patients deteriorate while waiting for an answer.

• Generalized Data Over Personalized Care – RCTs focus on “majority response,” discarding those who don’t fit the mold.

This isn’t science—it’s systemic neglect.

A System Rigged Against Individualized Care

We don’t see this approach in mainstream medicine because it threatens the financial strength of the pharmaceutical industry.

• Precision-targeted treatments mean fewer mass-produced drugs—which cuts into Big Pharma’s profit margins.

• A truly individualized medical system means fewer hospitalizations, fewer unnecessary interventions, and fewer chronic patients dependent on expensive lifelong medications.

• RCT-based gatekeeping ensures only patented, billion-dollar drugs get approval—while peptide and precision small molecule therapeutics remain buried under regulatory red tape.

This system is not designed to heal people—it is designed to sustain an industry. We Can’t Afford to Wait—Patients Are Deteriorating Now  (See link for article)

Further reading:

  1. https://www.nature.com/articles/s41591-021-01519-y
  2. https://jamanetwork.com/journals/jamaneurology/fullarticle/2829260?guestAccessKey=37236d8c-7c7d-4581-b9a3-a0bc7166de92&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=012725&adv=004812881201
  3. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2425

__________________

**Comment**

I was struck with how this article directly pertains to many of the problems in Lymeland.  RCTs have been the bane of research for Lyme/MSIDS.  Because mainstream medicine denies this complex illness can be chronic with persistent pathogen infection, and the inclusion of numerous coinfections, RCTs only include those who test positive on a test that misses nearly 90% of cases, and have a rash that is highly variable.  Maternal-fetal transmission was identified in 1985, but it took 27 years to recognize and investigate. While ‘the powers that be’ acknowledge it can be transmitted congenitally, they still claim it’s rare.  Due to this stance, doctors continue to fail to acknowledge and treat it.

Everything’s rare, until it isn’t.

The sickest patients are not represented in the research.

Category:

Activism, Lyme, research, Testing, Transmission

Lyme & Herxheimer Reaction in Newborn

https://danielcameronmd.com/lyme-disease-herxheimer-reaction-newborn/

Lyme disease and herxheimer reaction in newborn

Newborn with lyme disease and herxheimer reaction being examined by doctor.

The Herxheimer reaction, also referred to as a Jarisch-Herxheimer reaction, is “a transient clinical phenomenon that occurs in patients infected by spirochetes who undergo antibiotic treatment.”¹ It was first described in patients with syphilis but has also been associated with other spirochetal infections including leptospirosis, Lyme disease, and relapsing fever. The reaction is associated with the onset of new symptoms or a worsening of existing symptoms in patients receiving antibiotic treatment.

By 

In 2020, investigators published a case involving a 13-year-old boy with Lyme arthritis, a common manifestation of Lyme disease, who developed a Herxheimer reaction when treated with doxycycline. On the 7th day of treatment, the boy developed a low-grade fever and severe arthralgias with intense hip, ankle and cervical spine pain and myalgias.

You can read more about the 13-year-old boy’s case in an earlier blog “Herxheimer reaction in a 13-year-old boy with Lyme disease.” 

Newborn with herxheimer reaction

In their article “Lyme disease in a neonate complicated by the Jarisch–Herxheimer reaction,”  Prodanuk and colleagues² describe the case of a 21-day-old infant who was admitted to the hospital with decreased activity, poor feeding and abdominal distension.

The parents removed an engorged tick from the infant’s forearm 5 days earlier. An EM rash was present at the site of the tick bite.

“Given the erythema migrans lesion at the site from which the engorged tick was removed, we made a presumptive diagnosis of Lyme disease and administered IV ceftriaxone,” the authors write.

Two hours after treatment began, the infant developed a fever, tachycardia and other symptoms consistent with the Jarisch–Herxheimer reaction.

Testing for Lyme disease was negative.

Clinicians should also “be aware of the possibility of the Jarisch–Herxheimer reaction during the initial phase of treatment.”²

Several studies, they warn, indicate “newborns with findings consistent with early localized disease may also be at higher risk for disseminated disease.”

“Given the limited data for neonates and the possible predisposition of this population to disseminated Lyme disease, clinicians should strongly consider administering IV antibiotics to target Lyme disease,” the authors suggest.

Patients can experience a broad range of symptoms resulting from a herxheimer reaction, explains Nykytyuk and colleagues, including fever, severe polyarthralgias, myalgias, chills, hypotension, nonpruritic, nonpalpable rash, tachycardia, nausea, headache, strengthening of existing or occurrence of new symptoms of the underlying disease.¹

The exact cause of Jarisch-Herxheimer reactions is still unknown. “At first, the role of an endotoxin in the development of JHR was suggested, but later experimental studies showed that spirochetes do not have biologically active endotoxins,” the authors explained.¹

References:
  1. Dhakal A, Sbar E. Jarisch Herxheimer Reaction. [Updated 2022 Apr 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557820/
  2. Prodanuk M, Groves H, Arje D, Bitnun A. Lyme disease in a neonate complicated by the Jarisch-Herxheimer reaction. CMAJ. 2022 Jul 18;194(27):E939-E941. doi: 10.1503/cmaj.220112. PMID: 35851530; PMCID: PMC9299745.

______________

For more:

Category:

Lyme, Pregnancy, research, Testing, Ticks, Transmission, Treatment